Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Dermata Therapeutics, Inc.

Accession: 0001493152-26-050964

Filed: 2026-11-10

Period: 2026-11-10

CIK: 0001853816

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001853816

0001853816

2026-11-10

2026-11-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): November 10, 2026

DERMATA

THERAPEUTICS, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40739

86-3218736

(State

or other jurisdiction

(Commission

(IRS

Employer

of

incorporation)

File

Number)

Identification

No.)

3525

Del Mar Heights Rd., #322

San

Diego, CA

92130

(Address

of principal executive offices)

(Zip

Code)

(858)

800-2543

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of exchange on which registered

Common

Stock, par value $0.0001 per share

DRMA

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☒

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item

2.02. Results of Operation and Financial Condition.

On

November 10, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding

its results of operations for the quarter ended September 30, 2026, and provided a corporate update. A copy of the press release is furnished

under Item 2.02 as Exhibit 99.1.

The

information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed”

for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange

Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange

Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference

into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such

filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated November 10, 2026, issued by Dermata Therapeutics, Inc. entitled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026”

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

-2-

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

DERMATA

THERAPEUTICS, INC.

Dated:

November 10, 2026

By:

/s/

Gerald T. Proehl

Name:

Gerald

T. Proehl

Title:

President,

Chairman and Chief Executive Officer

-3-

EX-99.1

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Dermata

Therapeutics Provides Corporate Update

and

Reports Financial Results for the Third Quarter 2026

-

Dermata generates product revenue following the launch of its first commercial product,

Tome™

Foundational Treatment, on August 25, 2026 -

-

Tome Skincare ecommerce platform establishes a foundation for product growth through direct-to-consumer sales, subscriptions, and professional

skincare channels -

-

Positive topline results from a cosmetic clinical study in which participants demonstrated improvements across multiple measures of skin

appearance provides clinical support for the commercialization strategy of Tome Foundational Treatment as “Studied Skincare”

-

SAN

DIEGO, CA, November 10, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”),

a science-driven leader in dermatologic solutions focused on the development and commercialization of consumer and professional skincare

products, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2026.

“The

third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company

to a revenue-generating commercial skincare business,” commented Gerry Proehl, Dermata’s Chairman, President, and Chief Executive

Officer. “With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking

an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient,

consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder. We are excited about

the early interest in our Tome Foundational Treatment, including approximately 30% of orders generated via subscriptions. We believe

our subscribers will help establish the foundation for a scalable business with opportunities to expand consumer awareness, develop recurring

revenue through subscriptions, and introduce our products to skincare professionals.”

“Importantly,

our strategy extends beyond the launch of a single product. Recently, we initiated a clinical trial evaluating Tome Clearing Treatment,

our second planned commercial product for the treatment of acne, which we expect to launch in the first half of 2027,” continued

Mr. Proehl.

“Looking

ahead, our priorities are focused on increasing brand awareness of Tome, converting consumer interest into sales, expanding our distribution

opportunities, and building a broader portfolio of products powered by Bioneedle. We believe our combination of clinical expertise, differentiated

skincare technology, and direct-to-consumer commercialization provides an opportunity to build a growing skincare business with multiple

potential revenue streams and create long-term value for our shareholders,” concluded Mr. Proehl.

Recent

Corporate Highlights

● Launched

Tome Foundational Treatment and generated revenue. On August 25, 2026, Dermata officially

launched Tome Foundational Treatment, its first commercial skincare product, through its

direct-to-consumer website. The launch represents a significant milestone in the Company’s

strategic transition to commercial skincare and provides Dermata with its first opportunity

to generate revenue from product sales. Tome Foundational Treatment is a once-weekly skin

renewal treatment powered by the Company’s Bioneedle technology and is designed to

improve the appearance of skin tone, texture, fine lines, and dark spots.

● Announced

positive topline results from cosmetic clinical study of Tome Foundational Treatment.

In October 2026, Dermata announced positive topline results from its completed cosmetic clinical

study evaluating Tome Foundational Treatment in 31 participants over four weeks. The study

demonstrated improvements across multiple investigator-assessed measures of skin appearance,

including fine lines, hyperpigmentation, radiance, and overall appearance. More than 71%

of participants were graded as having overall improvement in skin appearance after just one

treatment. The Company believes these results support Tome’s positioning as “studied

skincare” and provides clinically supported content to enhance consumer education,

strengthen brand credibility, and support future marketing efforts.

● Continued

building brand awareness and market visibility for Tome. Surrounding the Tome Foundational

Treatment commercial launch, Dermata has focused on introducing Tome to consumers through

digital marketing, social media, public relations, and editorial outreach. The Company believes

that building awareness of Tome’s Bioneedle technology and once-weekly application

format will be important in supporting customer acquisition and expanding its presence in

the premium skincare market.

● Advanced

development of second commercial skincare product for acne. In October 2026, Dermata

announced enrollment of the first participant in a clinical trial evaluating Tome Clearing

Treatment, its second planned commercial product. Tome Clearing Treatment combines salicylic

acid, an FDA-recognized over-the-counter acne active ingredient, with the Company’s

Bioneedle technology in a once-weekly treatment regimen for the treatment of acne. The Company

expects to launch Tome Clearing Treatment in the first half of 2027, subject to successful

development and commercialization activities. Dermata believes the addition of a second product

could expand its addressable consumer market, create cross-selling opportunities, and diversify

its commercial revenue base.

Anticipated

Upcoming Milestones

● Drive

commercial growth of Tome Foundational Treatment. The Company plans to continue executing

its direct-to-consumer marketing strategy to increase brand awareness, attract new customers,

and encourage repeat purchases. Dermata intends to leverage clinical study results, consumer

education, and digital marketing to communicate the benefits of its Bioneedle technology

and support future sales growth.

● Expand

Tome’s professional skincare presence. Dermata intends to expand opportunities

to introduce Tome Foundational Treatment to aestheticians, dermatologists, and other skincare

professionals for in-office use and recommendations to their clients and patients. The Company

believes professional adoption could provide an additional revenue opportunity while supporting

broader consumer awareness and credibility of the Tome brand.

● Advance

Tome Clearing Treatment toward commercial launch in the first half of 2027. Dermata plans

to continue its clinical evaluation of Tome Clearing Treatment, with the goal of generating

evidence of its effect on acne to support its planned commercialization. The Company believes

its second product will expand Tome’s portfolio into the large consumer acne market

and support the Company’s strategy of building a multi-product skincare business.

● Continued

optimization of commercial operations and revenue opportunities. As Dermata progresses

through its initial commercialization period, the Company plans to evaluate customer purchasing

patterns, subscription participation, marketing performance, and other commercial metrics

to inform its growth strategy and capital allocation decisions.

Third

Quarter 2026 Financial Results

As

of September 30, 2026, the Company had $5.0 million in cash, cash equivalents and restricted cash, compared to $7.5 million as of December

31, 2025. The $2.5 million decrease in cash, cash equivalents and restricted cash for the nine months ended September 30, 2026, resulted

from $7.6 million of cash used in operations, and $0.2 million of cash used in investing activities, offset by financing activities of

approximately $2.0 million in net proceeds from the Company’s ATM and $3.2 million of net proceeds related to its August 2026 financing

transaction. The Company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.

Net

sales and cost of sales were $74,000 and $34,000, respectively, for the quarter ended September 30, 2026, related to sales of the Company’s

first commercial product, Tome Foundational Treatment. Gross profit was $40,000 for the quarter ended September 30, 2026, reflecting

an approximate 54% profit margin.

Research

and development expenses were $0.1 million for the quarter ended September 30, 2026, compared to $0.5 million for the quarter ended September

30, 2025. The $0.4 million decrease in research and development expenses resulted primarily from reallocation of employee duties to focus

on the commercial launch of the Company’s first product, Tome Foundational Treatment.

Selling,

general and administrative expenses were $2.8 million for the quarter ended September 30, 2026, compared to $1.3 million for the quarter

ended September 30, 2025. The increase in selling, general and administrative expenses of $1.5 million was primarily attributable to

the Company’s decision to prioritize the commercial launch of its first product, resulting in significant commercialization activities

during the quarter ended September 30, 2026. This resulted in an increase of $0.2 million of marketing and other commercialization expenses

and an increase of $0.5 million of compensation expense primarily due to a reallocation of employee duties from research and development

to selling, general and administrative expense, as a result of the shift in business focus towards commercialization. In addition, legal

fees increased by $0.8 million during the quarter ended September 30, 2026, due to ongoing litigation and new trademarks.

About

Tome Skincare

Tome

is Dermata’s skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal

meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in

science and history. Tome consists of skincare products utilizing a wild harvested freshwater sponge that has evolved over centuries

for consumers compelled by history and science to find potent natural products for their skincare routine. Dermata believes its Tome

skincare line can simplify existing skincare routines with essential ingredients designed to deliver results, without harmful extremes.

Start

your skincare story at Tome.

About

Dermata Therapeutics

Dermata

Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of both direct-to-consumer

and professional skincare solutions. The Company leverages its experience in clinical dermatology and its Bioneedle technology to develop

differentiated skincare products designed to address a variety of consumer skincare needs. Dermata’s first commercial product,

Tome Foundational Treatment, is now available at Tome, with additional innovations planned to follow. Dermata is headquartered

in San Diego, California.

For

more information, please visit Dermata.

Forward-Looking

Statements

Statements

in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s

current beliefs and expectations, and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown

risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to

prioritize direct-to-consumer (DTC) and over-the-counter (OTC) skincare products; the anticipated benefits of Dermata’s strategic

shift to prioritize DTC and OTC skincare products, including acceleration of its path to commercialization, and expansion into broader

consumer markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Clearing

Treatment; the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the

Company’s products and their ability to generate revenue for the Company; the Company’s expectations with regard to current

cash, cash equivalents, and restricted cash and the amount of time it will fund operations; and other factors described in the Company’s

filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words

as “may,” “could,” “should,” “would,” “believe,” “anticipate,”

“forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,”

“outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. These

statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual

events or results may differ materially from those projected in any of such statements due to various factors, including the risks and

uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata’s

filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements,

which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform

Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation

to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

DERMATA

THERAPEUTICS, INC.

Balance

Sheets

In thousands

USD

September 30,

2026

December 31,

2025

(unaudited)

Assets

Cash and cash equivalents

$ 4,822

$ 7,522

Restricted cash

200

-

Prepaid expenses and other current assets

583

342

Inventories

825

-

Non-current assets

205

-

Total assets

6,635

7,864

Liabilities

Accounts payable

1,620

461

Accrued liabilities

1,110

1,180

Total liabilities

2,730

1,641

Equity

3,905

6,223

Total

liabilities and equity

$ 6,635

$ 7,864

DERMATA

THERAPEUTICS, INC.

Statements

of Operations

(unaudited)

Quarter

Ended

September

30,

Nine

Months Ended

September

30,

In

thousands, except share and per share data

2026

2025

2026

2025

Net sales

$ 74

$ -

$ 74

$ -

Cost of sales

(34 )

-

(34 )

-

Gross profit

40

-

40

-

Operating expenses

Research and development (1)

143

504

739

2,403

Selling, general and administrative

(1)

2,755

1,256

7,099

3,470

Total operating expenses

2,898

1,760

7,838

5,873

Loss from operations

(2,858 )

(1,760 )

(7,798 )

(5,873 )

Interest income

37

69

162

176

Net

loss

$ (2,821 )

$ (1,691 )

$ (7,636 )

$ (5,697 )

Net loss per common

share, basic and diluted

$ (0.55 )

$ (1.65 )

$ (1.76 )

$ (6.64 )

Weighted average common

shares outstanding, basic and diluted

5,119,529

1,026,457

4,338,149

858,015

(1) Includes the following stock-based compensation

expense

Research and development

$ 4

$ 8

$ 22

$ 24

Selling, general and administrative

$ 38

$ 30

$ 105

$ 90

Investor

Contact:

Cliff

Mastricola

Investor

Relations

cmastricola@dermatarx.com

GRAPHIC

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (17712 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Nov. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Nov. 10, 2026

Entity File Number

001-40739

Entity Registrant Name

DERMATA

THERAPEUTICS, INC.

Entity Central Index Key

0001853816

Entity Tax Identification Number

86-3218736

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

3525

Del Mar Heights Rd.

Entity Address, Address Line Two

#322

Entity Address, City or Town

San

Diego

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

92130

City Area Code

(858)

Local Phone Number

800-2543

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

DRMA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

true

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration